We recommend providing the following details: Medical necessity justification with conservative treatment failure
Budget is limited
Never double-dose
These include: Lack of transparency on manufacturing location and practices While this vendor overall inspires confidence as to product quality with available test results, it provides little information on the manufacturing location or partners on either the website or product labels
Over 100 published preclinical studies have demonstrated protective and reparative effects of BPC-157 across tendon, muscle, bone, and gastrointestinal tissue
The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida